Tetraphase Pharmaceuticals announced that it will present at the Interscience Conference on Antimicrobial Agents and Chemotherapy the results of important research that supports the potential of the company’s next-generation antibiotics portfolio, including its lead candidate eravacycline in the treatment of difficult-to-treat bacterial infections. Data to be presented will highlight dosing of eravacycline in the company’s phase 2 clinical trial in complicated intra-abdominal infections as well as its activity in preclinical studies against neisseria gonorrhoeae, a common but increasingly resistant cause of gonococcal disease. Tetraphase recently dosed the first patient in its phase 3 clinical trial in cIAI. This marks the first of two planned phase 3 clinical trials. One in complicated intra-abdominal infections and one in complicated urinary tract infections that the company plans to initiate later this year. Data will also be shared on preclinical antibiotic candidate TP-271’s ability to combat the effects of aerosolized biological weapons, specifically the highly virulent pathogen francisella tularensis.